InMed Pharmaceuticals Inc. INM
Set alert
At close · Oct 30
After hours · Oct 30, 5:00 PM ET
- YTD
- +50.94%
- 1 year
- -13.51%
- Open
- 1.55
- Prev close
- 1.63
- Mkt cap
- 8.79M
- Vol
- 36.68K
- Avg vol
- 70.15K
- EPS
- -2.84
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.51
- High
- 1.61
- Forward P/E
- -0.75
- Beta
- 0.71
- Short ratio
- 0.12
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 11, 2025
- 50-d avg
- 4.94
- 200-d avg
- 5.37
- 1y target
- 0.00
2Y chart
Events in this range
- Nov 14, 2024Split: 1 for 20
- Nov 14, 2024Earnings: -54.2; estimate 0; surprise —%
- Feb 11, 2025Earnings: —; estimate 0; surprise —%
Signals (69)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 26, 2026 | 6 days ago |
| SMA: Bullish | Oct 23, 2026 | 1 week ago |
| MACD: Buy Signal | Sep 17, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 21, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 19, 2026 | 2 months ago |
| SMA: Bearish | Jul 30, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 29, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 23, 2026 | 3 months ago |
| RSI: Overbought | Jul 23, 2026 | 3 months ago |
| MACD: Sell Signal | Jun 8, 2026 | 4 months ago |
| RSI: Overbought | Jun 5, 2026 | 4 months ago |
| RSI: Overbought | Jun 3, 2026 | 5 months ago |
| SMA: Bullish | May 19, 2026 | 5 months ago |
| SMA: Bullish | May 19, 2026 | 5 months ago |
| MACD: Buy Signal | May 19, 2026 | 5 months ago |
| RSI: Overbought | May 19, 2026 | 5 months ago |
| MACD: Sell Signal | May 8, 2026 | 5 months ago |
| MACD: Buy Signal | Apr 7, 2026 | 6 months ago |
| RSI: Oversold | Mar 30, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 24, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 4, 2026 | 8 months ago |
| MACD: Sell Signal | Mar 3, 2026 | 8 months ago |
| RSI: Oversold | Mar 3, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 25, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 5, 2026 | 8 months ago |
| MACD: Buy Signal | Jan 5, 2026 | 10 months ago |
| MACD: Sell Signal | Dec 31, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 2, 2025 | 11 months ago |
| RSI: Oversold | Nov 18, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 17, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 14, 2025 | 11 months ago |
| RSI: Oversold | Nov 4, 2025 | 12 months ago |
| MACD: Sell Signal | Oct 13, 2025 | 1 year ago |
| SMA: Bearish | Oct 10, 2025 | 1 year ago |
| SMA: Bearish | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Oct 3, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 15, 2025 | 1 year ago |
| SMA: Bearish | Jul 15, 2025 | 1 year ago |
| SMA: Bullish | Jul 14, 2025 | 1 year ago |
| SMA: Bearish | Jul 7, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 7, 2025 | 1 year ago |
| SMA: Bullish | Jun 24, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 24, 2025 | 1 year ago |
| SMA: Bearish | Jun 11, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 10, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 2, 2025 | 1 year ago |
| SMA: Bearish | May 28, 2025 | 1 year ago |
| MACD: Sell Signal | May 22, 2025 | 1 year ago |
| MACD: Buy Signal | May 15, 2025 | 1 year ago |
| SMA: Bullish | May 14, 2025 | 1 year ago |
| SMA: Bearish | May 8, 2025 | 1 year ago |
| MACD: Sell Signal | May 7, 2025 | 1 year ago |
| SMA: Bullish | Apr 21, 2025 | 1 year ago |
| SMA: Bearish | Apr 16, 2025 | 1 year ago |
| SMA: Bullish | Apr 15, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 9, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 28, 2025 | 1 year ago |
| RSI: Oversold | Mar 28, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 14, 2025 | 1 year ago |
| SMA: Bearish | Jan 22, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 22, 2025 | 1 year ago |
| SMA: Bullish | Jan 17, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 17, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 8, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 3, 2025 | 1 year ago |
| MACD: Sell Signal | Dec 19, 2024 | 1 year ago |
Key statistics
- Market cap
- 3.36M
- Enterprise value
- 51.45M
- Trailing P/E
- 0.02
- Forward P/E
- -0.75
- PEG ratio
- 0.00
- Price / sales
- 0.73
- Price / book
- 4.53
- EPS (TTM)
- 230.40
- Beta
- 0.71
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -166.94%
- Revenue (TTM)
- 4.60M
- Revenue growth
- -44.50%
- Free cash flow
- -4.02M
- Total cash
- 6.61M
- Total debt
- 962.66K
- Return on equity
- -72.08%
- Shares outstanding
- 718.08K
- Short % of float
- 0.87%
- 50-day average
- 4.94
- 200-day average
- 5.37
Analyst view
Consensus: none
Next earnings
Feb 11, 2025
Expected Feb 11, 2025. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2025 | Dec 1, 2024 | 0.00 | — | — | — |
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -54.20 | — | — |
| Sep 27, 2024 | Jun 1, 2024 | 0.00 | -3.80 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -3.60 | — | — |
| Feb 13, 2024 | Dec 1, 2023 | 0.00 | -3.80 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -15.20 | — | — |
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, which is a small molecule compound acting as a selective dual CB1 /CB2 agonist; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- inmedpharma.com
News
- InMed Announces CVR Distribution Record Date in Connection with Proposed Merger
- InMed Pharmaceuticals Inc. (NASDAQ:INM) Shares Shorted: Short Interest Down 48.4% in September
- InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance
- InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update
- Financial Survey: InMed Pharmaceuticals (NASDAQ:INM) & Reviva Pharmaceuticals (NASDAQ:RVPH)
- InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline
- InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline
Your note
Sign in to keep a note on INM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS ERIC ASHLEY | Chief Executive Officer | Purchase | Feb 19, 2024 | 43,959 |
| HULL ANDREW HAROLD | Director | Purchase | Feb 20, 2024 | 38,258 |
| MANCINI ALEXANDRA DIANE JANET | Unknown | Sale | Jul 30, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Investments, LLC | 5.11% | 36,665 | 171.59K | Sep 29, 2024 |
| UBS Group AG | 1.48% | 10,602 | 49.62K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.39% | 2,833 | 13.26K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.35% | 2,515 | 11.77K | Sep 29, 2024 |
| HRT Financial LP | 0.27% | 1,918 | 8.98K | Sep 29, 2024 |
| Virtu Financial LLC | 0.20% | 1,421 | 6.65K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Pure Cannabis ETF | 5.80% | 41,665 | 194.99K | Oct 30, 2024 |